Abstract:Keywords: AI big data drug development Drug discovery repurposing References 1. Emily May LG, Karen T, Wendell M . Measuring the return from pharmaceutical innovation 2022 . Deloitte ( 2023 ). www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/measuring-return-from-pharmaceutical-innovation.html Google Scholar 2. Berdigaliyev N, Aljofan M . An overview of drug discovery and development . Future Med. Chem. 12(10), 939–947 ( 2020 ).CAS Google Scholar 3. Scannell JW, Blanckley A, Boldon H, Warrington B . Diagnosing the decline in pharmaceutical R&D efficiency . Nat. Rev. Drug Discov. 11(3), 191–200 ( 2012 ).Medline CAS Google Scholar 4. Jensen EJ . Research expenditures and the discovery of new drugs . J. Ind. Econ. 36(1), 83–95 ( 1987 ). Google Scholar 5. Jentzsch V, Osipenko L, Scannell JW, Hickman JA . Costs and causes of oncology drug attrition with the example of insulin-like growth factor-1 receptor inhibitors . JAMA Netw. Open 6(7), e2324977 ( 2023 ).Medline Google Scholar 6. AI's potential to accelerate drug discovery needs a reality check . Nature 622(7982), 217 ( 2023 ).Medline Google Scholar 7. Ringel MS, Scannell JW, Baedeker M, Schulze U . Breaking Eroom's law . Nat. Rev. Drug Discov. 19(12), 833–834 ( 2020 ).Medline CAS Google Scholar 8. WadmanM . Merck settles Vioxx lawsuits for $4.85 billion . Nature doi: 10.1038/450324b ( 2007 ). Google Scholar 9. Guengerich FP . Mechanisms of drug toxicity and relevance to pharmaceutical development . Drug Metab. Pharmacokinet. 26(1), 3–14 ( 2011 ).Medline CAS Google Scholar 10. van der Pol KH, Aljofan M, Blin O et al. Drug repurposing of generic drugs: challenges and the potential role for government . Appl. Health Econ. Health Policy 21(6), 831–840 (

New government drug repurposing programs: Opportunities and uncertainties

Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government

Drug repurposing: progress, challenges and recommendations

How drug repurposing can advance drug discovery: challenges and opportunities

Drug Repurposing: A Leading Strategy for New Threats and Targets

Can old drugs learn new tricks? Achieving registration and public subsidy listing for off-patent medicines with novel therapeutic applications

Repurposing of Drugs: Updates and New Perspectives

Drug Repurposing: Far Beyond New Targets for Old Drugs

Repurposing – second life for drugs

Drug repurposing: a systematic review on root causes, barriers and facilitators

Regulatory considerations and intellectual property rights of repurposed drugs

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines

Drug repurposing for rare: progress and opportunities for the rare disease community

Drug repurposing: An effective strategy to accelerate contemporary drug discovery

Drug discovery and development: the role of artificial intelligence in drug repurposing

Review of Drug Repositioning Approaches and Resources

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Current approaches in identification of a novel drug targets for drug repurposing

The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields

Drug repurposing for neglected and zoonotic diseases